Big Pharma Is Going Holiday Shopping. Who's Next?
In a previous article, I had pointed at Aurinia Pharmaceuticals as a potential takeover candidate. Since then, the biopharma company has been rumored as an acquisition target for Bristol Myers Squibb, with other giants such as Roche Holdings and GlaxoSmithKline also considered to be courting the small biotech.
Let's look at three other drugmakers that large pharma companies with cash to spend might think about acquiring.
A major concern with today's treatments for autoimmune and inflammatory diseases is that they also suppress patients' immune systems, leaving them more susceptible to infections. Biotech ChemoCentryx (NASDAQ: CCXI) is trying to change all of this with its drug for rare autoimmune diseases, Tavneos. The company believes the drug effectively targets the chronic inflammatory pathway without suppressing the immune system.
Source Fool.com
